Startups
PharmaBiome develops a pipeline for the use of beneficial gut bacteria as an innovative, standardized and safe therapeutic product to treat diseases caused by functional deficiencies in the microbiome (i.e. gut flora), with an initial focus on ulcerative colitis (UC). Using its proprietary technology platform including isolation, cultivation and rational assembly of intestinal bacterial mixtures, PharmaBiome develops tailored microbiome products. The flexibility and speed of development are a unique advantage to penetrate the multibillion markets of untreatable intestinal diseases.
Overview
Location
Switzerland, Zurich
Total raised
$1.87M
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| VentureLab | venturelab.swiss |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 8, 2020 | PharmaBiome secures CHF 1.75 million bridge funding | |
| Jul 8, 2020 | PharmaBiome raises CHF 1.75 million to advance preclinical development and welcomes new board members | PharmaBiome has secured CHF 1.75 million in bridge financing from current shareholders and new investors, including newly elected members of the board. The new funds will allow the company to advance the preclinical development of its most ... |
| Jul 8, 2020 | PharmaBiome secures CHF 1.75 million bridge funding | Using its unique and proprietary technology platform, PharmaBiome develops therapeutics consisting of defined, pharma-grade, bacterial consortia for the treatment of microbiome-related diseases. PharmaBiome’s microbiome-based products can b... |
| Jul 8, 2020 | PharmaBiome raises CHF 1.75 million to advance preclinical development and welcomes new board members | PharmaBiome raises CHF 1.75 million to advance preclinical development and welcomes new board members 08.07.2020 09:48, Isabelle Mitchell linkedIn facebook twitter instagram youtube --> PharmaBiome AG, a pioneer in next-generation microb... |
| Apr 23, 2020 | Microcaps gewinnt den ZKB Pionierpreis Technopark 2020 | Wir alle haben täglich mit unzähligen Produkten zu tun, in denen Mikrokapseln zum Einsatz kommen. Das Spektrum reicht von Medikamenten über Kosmetika bis hin zu Haushaltsprodukten. Das Problem ist aber: Bisher lässt die Herstellung dieser K... |
| Apr 23, 2020 | Microcaps gewinnt den ZKB Pionierpreis Technopark 2020 | |
| Mar 5, 2020 | Die Finalisten des ZKB Pionierpreis Technopark stehen fest | |
| Mar 5, 2020 | Die Finalisten des ZKB Pionierpreis Technopark stehen fest | Der mit rund 100‘000 Franken dotierte ZKB Pionierpreis Technopark wird seit 2001 jedes Jahr von der Zürcher Kantonalbank und der Stiftung Technopark Zürich verliehen. Im Mittelpunkt stehen in der Regel Startups mit Innovationen im Bereich d... |
| Jan 21, 2020 | BaseLaunch accelerator nominates 4 startups for phase 2 |
Show more
Reviews 0
FAQ about PharmaBiome AG
How much funding has PharmaBiome AG raised?
PharmaBiome AG has raised $1.87M in total across 1 funding round.
Who has invested in PharmaBiome AG?
Parsers VC lists 2 investors of PharmaBiome AG, among them VentureLab.
What has the press written about PharmaBiome AG?
Parsers VC has collected 21 articles mentioning PharmaBiome AG, among them “PharmaBiome secures CHF 1.75 million bridge funding” (Jul 8, 2020) and “PharmaBiome raises CHF 1.75 million to advance preclinical development and welcomes new board members” (Jul 8, 2020).
Is PharmaBiome AG still active?
Yes, PharmaBiome AG is active; its latest activity on Parsers VC dates from Mar 27, 2023.